Regenerative approaches for the treatment of early OA

L. de Girolamo, E. Kon, G. Filardo, A. G. Marmotti, F. Soler, G. M. Peretti, F. Vannini, H. Madry, S. Chubinskaya

Research output: Contribution to journalReview article

Abstract

The diagnosis and the prompt treatment of early osteoarthritis (OA) represent vital steps for delaying the onset and progression of fully blown OA, which is the most common form of arthritis, involving more than 10 % of the world’s population older than 60 years of age. Nonsurgical treatments such as physiotherapy, anti-inflammatory medications, and other disease-modifying drugs all have modest and short-lasting effect. In this context, the biological approaches have recently gained more and more attention. Growth factors, blood derivatives, such as platelet concentrates, and mesenchymal adult stem cells, either expanded or freshly isolated, are advocated amongst the most promising tool for the treatment of OA, especially in the early phases. Primarily targeted towards focal cartilage defects, these biological agents have indeed recently showed promising results to relieve pain and reduce inflammation in patients with more advanced OA as well, with the final aim to halt the progression of the disease and the need for joint replacement. However, despite of a number of satisfactory in vitro and pre-clinical studies, the evidences are still limited to support their clinical efficacy in OA setting. Level of evidence V.

Original languageEnglish
Pages (from-to)1826-1835
Number of pages10
JournalKnee Surgery, Sports Traumatology, Arthroscopy
Volume24
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Osteoarthritis
Replacement Arthroplasties
Therapeutics
Adult Stem Cells
Biological Factors
Mesenchymal Stromal Cells
Arthritis
Cartilage
Disease Progression
Intercellular Signaling Peptides and Proteins
Anti-Inflammatory Agents
Blood Platelets
Inflammation
Pain
Pharmaceutical Preparations
Population

Keywords

  • Cartilage
  • Growth factors
  • Mesenchymal stem cells
  • Molecular therapy
  • Osteoarthritis

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Surgery

Cite this

Regenerative approaches for the treatment of early OA. / de Girolamo, L.; Kon, E.; Filardo, G.; Marmotti, A. G.; Soler, F.; Peretti, G. M.; Vannini, F.; Madry, H.; Chubinskaya, S.

In: Knee Surgery, Sports Traumatology, Arthroscopy, Vol. 24, No. 6, 01.06.2016, p. 1826-1835.

Research output: Contribution to journalReview article

de Girolamo, L. ; Kon, E. ; Filardo, G. ; Marmotti, A. G. ; Soler, F. ; Peretti, G. M. ; Vannini, F. ; Madry, H. ; Chubinskaya, S. / Regenerative approaches for the treatment of early OA. In: Knee Surgery, Sports Traumatology, Arthroscopy. 2016 ; Vol. 24, No. 6. pp. 1826-1835.
@article{3097e237ade44f6ea8e48debc36a9d27,
title = "Regenerative approaches for the treatment of early OA",
abstract = "The diagnosis and the prompt treatment of early osteoarthritis (OA) represent vital steps for delaying the onset and progression of fully blown OA, which is the most common form of arthritis, involving more than 10 {\%} of the world’s population older than 60 years of age. Nonsurgical treatments such as physiotherapy, anti-inflammatory medications, and other disease-modifying drugs all have modest and short-lasting effect. In this context, the biological approaches have recently gained more and more attention. Growth factors, blood derivatives, such as platelet concentrates, and mesenchymal adult stem cells, either expanded or freshly isolated, are advocated amongst the most promising tool for the treatment of OA, especially in the early phases. Primarily targeted towards focal cartilage defects, these biological agents have indeed recently showed promising results to relieve pain and reduce inflammation in patients with more advanced OA as well, with the final aim to halt the progression of the disease and the need for joint replacement. However, despite of a number of satisfactory in vitro and pre-clinical studies, the evidences are still limited to support their clinical efficacy in OA setting. Level of evidence V.",
keywords = "Cartilage, Growth factors, Mesenchymal stem cells, Molecular therapy, Osteoarthritis",
author = "{de Girolamo}, L. and E. Kon and G. Filardo and Marmotti, {A. G.} and F. Soler and Peretti, {G. M.} and F. Vannini and H. Madry and S. Chubinskaya",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s00167-016-4125-y",
language = "English",
volume = "24",
pages = "1826--1835",
journal = "Knee Surgery, Sports Traumatology, Arthroscopy",
issn = "0942-2056",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Regenerative approaches for the treatment of early OA

AU - de Girolamo, L.

AU - Kon, E.

AU - Filardo, G.

AU - Marmotti, A. G.

AU - Soler, F.

AU - Peretti, G. M.

AU - Vannini, F.

AU - Madry, H.

AU - Chubinskaya, S.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The diagnosis and the prompt treatment of early osteoarthritis (OA) represent vital steps for delaying the onset and progression of fully blown OA, which is the most common form of arthritis, involving more than 10 % of the world’s population older than 60 years of age. Nonsurgical treatments such as physiotherapy, anti-inflammatory medications, and other disease-modifying drugs all have modest and short-lasting effect. In this context, the biological approaches have recently gained more and more attention. Growth factors, blood derivatives, such as platelet concentrates, and mesenchymal adult stem cells, either expanded or freshly isolated, are advocated amongst the most promising tool for the treatment of OA, especially in the early phases. Primarily targeted towards focal cartilage defects, these biological agents have indeed recently showed promising results to relieve pain and reduce inflammation in patients with more advanced OA as well, with the final aim to halt the progression of the disease and the need for joint replacement. However, despite of a number of satisfactory in vitro and pre-clinical studies, the evidences are still limited to support their clinical efficacy in OA setting. Level of evidence V.

AB - The diagnosis and the prompt treatment of early osteoarthritis (OA) represent vital steps for delaying the onset and progression of fully blown OA, which is the most common form of arthritis, involving more than 10 % of the world’s population older than 60 years of age. Nonsurgical treatments such as physiotherapy, anti-inflammatory medications, and other disease-modifying drugs all have modest and short-lasting effect. In this context, the biological approaches have recently gained more and more attention. Growth factors, blood derivatives, such as platelet concentrates, and mesenchymal adult stem cells, either expanded or freshly isolated, are advocated amongst the most promising tool for the treatment of OA, especially in the early phases. Primarily targeted towards focal cartilage defects, these biological agents have indeed recently showed promising results to relieve pain and reduce inflammation in patients with more advanced OA as well, with the final aim to halt the progression of the disease and the need for joint replacement. However, despite of a number of satisfactory in vitro and pre-clinical studies, the evidences are still limited to support their clinical efficacy in OA setting. Level of evidence V.

KW - Cartilage

KW - Growth factors

KW - Mesenchymal stem cells

KW - Molecular therapy

KW - Osteoarthritis

UR - http://www.scopus.com/inward/record.url?scp=84971294631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971294631&partnerID=8YFLogxK

U2 - 10.1007/s00167-016-4125-y

DO - 10.1007/s00167-016-4125-y

M3 - Review article

AN - SCOPUS:84971294631

VL - 24

SP - 1826

EP - 1835

JO - Knee Surgery, Sports Traumatology, Arthroscopy

JF - Knee Surgery, Sports Traumatology, Arthroscopy

SN - 0942-2056

IS - 6

ER -